文献速递胸部肿瘤

外周血DNA甲基化作为石棉暴露人群恶性胸膜间皮瘤的潜在生物标志物

Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
PubMed 文献 · J Thorac Oncol · 2018-11-05

在163例恶性胸膜间皮瘤(MPM)病例和137例无癌对照中,用全基因组甲基化芯片寻找石棉暴露人群的血液DNA甲基化标志物,训练集82例病例和68例对照,测试集81例病例和69例对照。发现800余个差异甲基化位点,主要涉及免疫系统相关基因;测试集中结合DNA甲基化与石棉暴露可提高病例/对照区分度(AUC=0.89 vs AUC=0.81,DeLong检验p=0.0013)。作者认为结果为进一步在前瞻性研究中探索血液DNA甲基化谱用于识别MPM癌变过程早期变化提供了依据。

要点

  • 在石棉暴露人群中,MPM病例与对照全血DNA存在差异甲基化,涉及800余个CpG位点(pfdr<0.05)。
  • 测试集中结合DNA甲基化与石棉暴露的模型AUC=0.89,高于不含甲基化模型的AUC=0.81(DeLong检验p=0.0013)。
  • 作者认为需在前瞻性研究中进一步探讨血液DNA甲基化谱用于识别MPM癌变过程早期变化的潜在用途。

核心结论

  • 在石棉暴露的MPM病例与对照的全血DNA中鉴定出差异甲基化特征。
  • 作者认为结果为进一步在前瞻性研究中探讨血液DNA甲基化谱用于识别MPM癌变过程早期变化的潜在用途提供了依据。

研究设计与样本

  • 研究使用全基因组甲基化芯片,在来自同一地区的163例MPM病例和137例无癌对照中寻找石棉暴露人群的MPM血液DNA甲基化标志物。
  • 训练集包含82例MPM病例和68例对照,测试集包含81例MPM病例和69例对照。

主要发现

  • MPM病例与对照间发现差异甲基化证据,超过800个胞嘧啶-鸟嘌呤二核苷酸位点(pfdr<0.05),主要位于免疫系统相关基因。
  • 基于排名靠前的差异甲基化信号,7个单CpG位点和5个协同甲基化基因组区域在测试集中以相似效应量重复(pfdr<0.05)。
  • 排名靠前的低甲基化单CpG位点位于FOXK1基因,病例 versus 对照效应量小于-0.15,训练集和测试集pfdr均<0.05。
  • 测试集中,包含DNA甲基化与石棉暴露的模型 versus 不包含甲基化的模型,AUC=0.89 versus AUC=0.81,DeLong检验p=0.0013,提示病例/对照区分度提高。

关键数值与推荐

  • 差异甲基化位点超过800个CpG位点,pfdr<0.05。
  • 7个单CpG位点和5个协同甲基化基因组区域在测试集中重复,pfdr<0.05。
  • FOXK1基因低甲基化单CpG位点病例 versus 对照效应量小于-0.15,训练集和测试集pfdr均<0.05。
  • 测试集中包含DNA甲基化与石棉暴露的模型AUC=0.89 versus 不包含甲基化模型的AUC=0.81,DeLong检验p=0.0013。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 作者在结论中提出需在前瞻性研究中进一步探讨血液DNA甲基化谱用于识别MPM癌变过程早期变化的潜在用途。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive tumor strongly associated with asbestos exposure. Patients are usually diagnosed when current treatments have limited benefits, highlighting the need for noninvasive early diagnostic tests to monitor asbestos-exposed people. METHODS: We used a genome-wide methylation array to identify, in asbestos-exposed subjects, novel blood DNA methylation markers of MPM in 163 MPM cases and 137 cancer-free controls (82 MPM cases and 68 controls, training set; replication in 81 MPM cases and 69 controls, test set) sampled from the same areas. RESULTS: Evidence of differential methylation between MPM cases and controls was found (more than 800 cytosine-guanine dinucleotide sites, false discovery rate p value (pfdr) < 0.05), mainly in immune system-related genes. Considering the top differentially methylated signals, seven single- cytosine-guanine dinucleotides and five genomic regions of coordinated methylation replicated with similar effect size in the test set (pfdr < 0.05). The top hypomethylated single-CpG (cases versus controls effect size less than -0.15, pfdr < 0.05 in both the training and test sets) was detected in FOXK1 (Forkhead-box K1) gene, an interactor of BAP1 which was found mutated in MPM tissue and as germline mutation in familial MPM. In the test set, comparison of receiver operating characteristic curves and the area under the curve (AUC) of two models, including or excluding methylation, showed a significant increase in case/control discrimination when considering DNA methylation together with asbestos exposure (AUC = 0.81 versus AUC = 0.89, DeLong's test p = 0.0013). CONCLUSIONS: We identified signatures of differential methylation in DNA from whole blood between asbestos exposed MPM cases and controls. Our results provide the rationale to further investigate, in prospective studies, the potential use of blood DNA methylation profiles for the identification of early changes related to the MPM carcinogenic process.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Guarrera S, Viberti C, Cugliari G, et al. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects. J Thorac Oncol. 2018. PMID: 30408567. doi:10.1016/j.jtho.2018.10.163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。